Dev Karan, PhD

Publications

• Inflammasomes: Emerging Central Players in Cancer Immunology and Immunotherapy.

  (Karan D.) Front Immunol. 2018;9:3028.

• Withaferin A Associated Differential Regulation of Inflammatory Cytokines.

  (Dubey S, Yoon H, Cohen MS, Nagarkatti P, Nagarkatti M, Karan D.) Front Immunol. 2018;9:195.

• Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.

  (Karan D.) Vaccine. 2017 10 13;35(43):5794-5798.

• Expression analysis of inflammasome sensors and implication of NLRP12 inflammasome in prostate cancer.

  (Karan D, Tawfik O, Dubey S.) Sci Rep. 2017 06 29;7(1):4378.

• From Inflammation to Prostate Cancer: The Role of Inflammasomes.

  (Karan D, Dubey S.) Adv Urol. 2016;2016:3140372.

• Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen?

  (Karan D.) Immunotherapy. 2013 Sep;5(9):907-10.

• Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity.

  (Karan D, Van Veldhuizen P.) Immunotherapy. 2012 Jun;4(6):577-80.

• Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

  (Karan D, Holzbeierlein JM, Van Veldhuizen P, Thrasher JB.) Nat Rev Urol. 2012 May 29;9(7):376-85.

• Inflammation-associated regulation of the macrophage inhibitory cytokine (MIC-1) gene in prostate cancer.

  (Dubey S, Vanveldhuizen P, Holzbeierlein J, Tawfik O, Thrasher JB, Karan D.) Oncol Lett. 2012 May;3(5):1166-1170.

• Adenovirus-based immunotherapy for prostate cancer

  (Dubey S, Van Veldhuizen P, Karan D.) Current Cancer Therapy Reviews. 2012;8(4):264-270.

• Prostate cancer immunotherapy

  (Karan D, Van Veldhuizen P.) Current Cancer Therapy Reviews. 2012;8(4):237.

• Prostate cancer immunotherapy: An evolving field

  (Hashmi M, Karan D, Phadke S, Saunthararajah Y, Kambhampati S, Van Veldhuizen P.) Current Cancer Therapy Reviews. 2012;8(4):274-282.